As the expression level of mitosis exit regulators was positively correlating with TP53 mutation, targeting at these regulators (APC/C, Aurora kinases, PLK1, KIFs) seems to be a reasonable strategy for TP53 mutant AML patients. This evidence concerns the gene TP53 and acute myeloid leukemia.